| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The precise molecular target of dihydroisocucurbitacin B has not been definitively identified in the available literature. As a cucurbitacin analogue, it may share mechanisms with other members of this family, which often target the STAT3 signaling pathway, the actin cytoskeleton, or the PCSK9/LDLR pathway. For the related compound isocucurbitacin B, direct binding to Caveolin 1 (CAV1) has been demonstrated. Additionally, dihydrocucurbitacin B (a closely related analogue) has been reported to promote LDL uptake by upregulating LDLR protein through a PCSK9-dependent mechanism . Further target identification studies are needed for this specific compound.
|
|---|---|
| ln Vitro |
Dihydroisocucurbitacin B exhibits significant cytotoxicity against a panel of human tumor cell lines. According to the original isolation study from Trichosanthes kirilowii, this compound demonstrated potent growth inhibitory effects against A-549 (lung carcinoma), SK-OV-3 (ovarian adenocarcinoma), SK-MEL-2 (skin melanoma), XF-498 (central nervous system tumor), and HCT-15 (colon adenocarcinoma) cells . Additionally, another study reported that dihydroisocucurbitacin B was isolated as a cytotoxic principle from Bolbostemma paniculatum via bioassay-guided screening, with activity determined using MTT assays . The cytotoxicity was observed with exceptionally high potency, consistent with the activity profile of cucurbitacin family compounds.
|
| ln Vivo |
For example, the closely related dihydrocucurbitacin B has been studied for its lipid-lowering properties via upregulation of LDLR . These findings suggest that dihydroisocucurbitacin B may have potential for in vivo efficacy, but direct animal model studies specifically for this compound are required to confirm its pharmacological effects in living systems.
|
| Enzyme Assay |
However, for the isolation and characterization of this compound, standard phytochemical techniques such as NMR spectroscopy, UV, IR, and mass spectrometry were used to elucidate its structure . For target engagement studies of related cucurbitacins, techniques such as Western blot analysis have been employed to measure protein level changes (e.g., LDLR and PCSK9) . Cellular Thermal Shift Assay (CETSA) is another technique used to confirm direct binding to putative protein targets.
|
| Cell Assay |
he cytotoxicity of dihydroisocucurbitacin B has been evaluated using standard in vitro anticancer screening methods. The original study utilized cultured human tumor cell lines including A-549, SK-OV-3, SK-MEL-2, XF-498, and HCT-15 . A typical protocol involves seeding cells in 96-well plates, allowing attachment overnight, then treating with varying concentrations of dihydroisocucurbitacin B for 48-72 hours. Cell viability is assessed using colorimetric methods such as SRB (sulforhodamine B) or MTT assays, which measure total cellular protein content or mitochondrial activity. MTT assay has been specifically employed for cytotoxicity testing of this compound from Bolbostemma paniculatum .
|
| Animal Protocol |
Standard in vivo protocols for cucurbitacin compounds typically involve administration via intraperitoneal injection or oral gavage in rodent models (e.g., mice or rats). For low water solubility compounds like dihydroisocucurbitacin B (logP ~2.3), formulation strategies may include DMSO/PEG300/Tween 80/saline mixtures for injection or 0.5% CMC-Na for oral suspension .
|
| ADME/Pharmacokinetics |
Based on its physicochemical properties, the compound has a logP value of approximately 2.3, a topological polar surface area (TPSA) of 138.0 Ų, and a solubility (LogS) of -4.45, indicating low water solubility . It has 3 hydrogen bond donors and 8 acceptors, which meets Lipinski‘s rule of five violations? The high molecular complexity (1170) suggests challenging absorption characteristics. For in vivo formulation, solubility enhancers such as DMSO, PEG300, Tween 80, or cyclodextrins are recommended .
|
| Toxicity/Toxicokinetics |
Cucurbitacins as a class are known to exhibit significant cytotoxicity at low concentrations, which underlies their antitumor activity but also raises concerns for potential off-target toxicity . The compound has been isolated and identified as an active principle with potent in vitro cytotoxicity, suggesting careful handling is required. It should be emphasized that this compound is strictly for research use only and is not approved for human therapeutic use .
|
| References | |
| Additional Infomation |
It has been reported that Marah oregana and Cucumis melo contain 23,24-dihydroisocucurbitacin B, and relevant data are available.
|
| Molecular Formula |
C32H48O8
|
|---|---|
| Molecular Weight |
560.72
|
| Exact Mass |
560.334
|
| CAS # |
68354-21-2
|
| PubChem CID |
14354067
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
695.3±55.0 °C at 760 mmHg
|
| Flash Point |
216.5±25.0 °C
|
| Vapour Pressure |
0.0±5.0 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
2.31
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
40
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(=O)OC(C)(C)CCC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(CC(=O)C(O)C4(C)C)C3(C)C(=O)CC12C |c:22|
|
| InChi Key |
BCSNGCDMERUCFL-UWEIAPOQSA-N
|
| InChi Code |
InChI=1S/C32H48O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,19,21-22,25-26,35,38-39H,11-16H2,1-9H3/t19-,21-,22+,25+,26+,29+,30-,31+,32+/m1/s1
|
| Chemical Name |
[(6R)-6-[(3R,8S,9R,10R,13R,14S,16R,17R)-3,16-dihydroxy-4,4,9,13,14-pentamethyl-2,11-dioxo-3,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxoheptan-2-yl] acetate
|
| Synonyms |
[6-(3,16-dihydroxy-4,4,9,13,14-pentamethyl-2,11-dioxo-3,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxoheptan-2-yl] acetate; 68354-21-2; 23,24-dihydroisocucurbitacin B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7834 mL | 8.9171 mL | 17.8342 mL | |
| 5 mM | 0.3567 mL | 1.7834 mL | 3.5668 mL | |
| 10 mM | 0.1783 mL | 0.8917 mL | 1.7834 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
